{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:26:56Z","timestamp":1786980416327,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016062","name":"Stichting Metakids","doi-asserted-by":"publisher","award":["2018-083 and 2021-094"],"award-info":[{"award-number":["2018-083 and 2021-094"]}],"id":[{"id":"10.13039\/100016062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030872","name":"EMC | Erasmus MC Sophia Kinderziekenhuis","doi-asserted-by":"publisher","award":["S18-59"],"award-info":[{"award-number":["S18-59"]}],"id":[{"id":"10.13039\/100030872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OP20-04"],"award-info":[{"award-number":["W.OP20-04"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008358","name":"Hersenstichting","doi-asserted-by":"publisher","award":["DR-2021-00386"],"award-info":[{"award-number":["DR-2021-00386"]}],"id":[{"id":"10.13039\/501100008358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010573","name":"Stichting Dioraphte","doi-asserted-by":"publisher","award":["20210367"],"award-info":[{"award-number":["20210367"]}],"id":[{"id":"10.13039\/501100010573","id-type":"DOI","asserted-by":"publisher"}]},{"name":"For Wishdom Foundation"},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWA.1389.20.049"],"award-info":[{"award-number":["NWA.1389.20.049"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2025,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We present the SWAP design, a novel, structurally cohesive IGF2-based tag for modular receptor targeting during gene therapy for lysosomal storage disorders (LSDs). We found that IGF2\u2019s central loop is critical for high-affinity binding to the insulin receptor (IR) and IGF1 receptor (IGF1R)\u2014both involved in glucose homeostasis\u2014but is not required for interaction with the cation independent mannose 6-phosphate\/IGF2 receptor (CI-M6P\/IGF2R)\u2014a key target for lysosomal delivery. This formed the basis for designing the Substitution of the central-loop With Augmenting Peptides (SWAP) tag. By replacing the central loop with alternative epitopes, SWAP ensures high-affinity multimodal receptor targeting while maintaining structural integrity. In vivo, lentiviral gene therapy employing IDS fused to SWAP variants containing ApoE and RAP12x2 inserts corrected Hunter disease pathology across multiple tissues, including liver, spleen, heart, bone, and brain, matching the efficacy of the traditional IGF2 tag. These findings position SWAP as a novel and effective tag design for IGF2-based therapeutics with a more favourable ligand\u2013receptor interaction.<\/jats:p>","DOI":"10.1038\/s44321-025-00314-3","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T10:09:01Z","timestamp":1759140541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Domain-substituted IGF2 tag modulates targeting of lentiviral gene therapy for Hunter syndrome"],"prefix":"10.1038","volume":"17","author":[{"given":"Fabio","family":"Catalano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0837-1993","authenticated-orcid":false,"given":"Dejan","family":"Stevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Zundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa F","family":"Huizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zina","family":"Dammou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva C","family":"Vlaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6841-2210","authenticated-orcid":false,"given":"Drosos","family":"Katsavelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen C","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannerieke J M P","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeralda","family":"Oussoren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J G","family":"Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7042-2482","authenticated-orcid":false,"given":"W W M Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"314_CR1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, Ronneberger O, Willmore L, Ballard AJ, Bambrick J et al (2024) Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630:493\u2013500","journal-title":"Nature"},{"key":"314_CR2","first-page":"1","volume":"15","author":"W An","year":"2024","unstructured":"An W, Hall C, Li J, Hung A, Wu J, Park J, Wang L, Bai XC, Choi E (2024) Activation of the insulin receptor by insulin-like growth factor 2. Nat Commun 15:1\u201317","journal-title":"Nat Commun"},{"key":"314_CR3","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.3390\/cells9102276","volume":"9","author":"AJ Blyth","year":"2020","unstructured":"Blyth AJ, Kirk NS, Forbes BE (2020) Understanding IGF-II action through insights into receptor binding and activation. Cells 9:2276","journal-title":"Cells"},{"key":"314_CR4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.emboj.7601938","volume":"27","author":"J Brown","year":"2008","unstructured":"Brown J, Delaine C, Zaccheo OJ, Siebold C, Gilbert RJ, Van Boxel G, Denley A, Wallace JC, Hassan AB, Forbes BE et al (2008) Structure and functional analysis of the IGF-II\/IGF2R interaction. EMBO J 27:265\u2013276","journal-title":"EMBO J"},{"key":"314_CR5","doi-asserted-by":"crossref","first-page":"101281","DOI":"10.1016\/j.molmet.2021.101281","volume":"53","author":"CR Bruce","year":"2021","unstructured":"Bruce CR, Hamley S, Ang T, Howlett KF, Shaw CS, Kowalski GM (2021) Translating glucose tolerance data from mice to humans: Insights from stable isotope labelled glucose tolerance tests. Mol Metab 53:101281","journal-title":"Mol Metab"},{"key":"314_CR6","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0693-2","volume":"12","author":"BJ Byrne","year":"2017","unstructured":"Byrne BJ, Geberhiwot T, Barshop BA, Barohn R, Hughes D, Bratkovic D, Desnuelle C, Laforet P, Mengel E, Roberts M et al (2017) A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease. Orphanet J Rare Dis 12:144","journal-title":"Orphanet J Rare Dis"},{"key":"314_CR7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/hum.2023.177","volume":"35","author":"F Catalano","year":"2024","unstructured":"Catalano F, Vlaar EC, Dammou Z, Katsavelis D, Huizer TF, Zundo G, Hoogeveen-Westerveld M, Oussoren E, van den Hout HJMP, Schaaf G et al (2024) Lentiviral gene therapy for mucopolysaccharidosis II with tagged iduronate 2-sulfatase prevents life-threatening pathology in peripheral tissues but fails to correct cartilage. Hum Gene Ther 35:256\u2013268","journal-title":"Hum Gene Ther"},{"key":"314_CR8","doi-asserted-by":"crossref","first-page":"101149","DOI":"10.1016\/j.omtm.2023.101149","volume":"31","author":"F Catalano","year":"2023","unstructured":"Catalano F, Vlaar EC, Katsavelis D, Dammou Z, Huizer TF, van den Bosch JC, Hoogeveen-Westerveld M, van den Hout HJMP, Oussoren E, Ruijter GJG et al (2023) Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II. Mol Ther Methods Clin Dev 31:101149","journal-title":"Mol Ther Methods Clin Dev"},{"key":"314_CR9","doi-asserted-by":"crossref","first-page":"A427","DOI":"10.1086\/302500","volume":"65","author":"BH Chen","year":"1999","unstructured":"Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai P-C, Roetker NS, Just AC, Demerath EW, Guan W et al (1999) Targeted disruption of the mouse iduronate sulfatase gene. Am J Hum Genet 65:A427\u2013A427","journal-title":"Am J Hum Genet"},{"key":"314_CR10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","volume":"44","author":"D Concolino","year":"2018","unstructured":"Concolino D, Deodato F, Parini R (2018) Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr 44:120","journal-title":"Ital J Pediatr"},{"key":"314_CR11","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1021\/bi036208p","volume":"43","author":"JE Croy","year":"2004","unstructured":"Croy JE, Brandon T, Komives EA (2004) Two apolipoprotein E mimetic peptides, apoE(130-149) and apoE(141-155) 2, bind to LRP1. Biochemistry 43:7328\u20137335","journal-title":"Biochemistry"},{"key":"314_CR12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1172\/JCI5656","volume":"105","author":"J-C Devedjian","year":"2000","unstructured":"Devedjian J-C, Gros L, Bosch F (2000) Transgenic mice overexpressing insulin-like growth factor-II in \u03b2 cells develop type 2 diabetes. J Clin Invest 105:731\u2013740","journal-title":"J Clin Invest"},{"key":"314_CR13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1086\/499280","volume":"193","author":"CB Dobson","year":"2006","unstructured":"Dobson CB, Sales SD, Hoggard P, Wozniak MA, Crutcher KA (2006) The receptor\u2010binding region of human apolipoprotein E has direct anti\u2010infective activity. J Infect Dis 193:442\u2013450","journal-title":"J Infect Dis"},{"key":"314_CR14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2022.10.017","volume":"27","author":"Y Dogan","year":"2022","unstructured":"Dogan Y, Barese CN, Schindler JW, Yoon JK, Unnisa Z, Guda S, Jacobs ME, Oborski C, Maiwald T, Clarke DL et al (2022) Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease. Mol Ther Methods Clin Dev 27:464\u2013487","journal-title":"Mol Ther Methods Clin Dev"},{"key":"314_CR15","doi-asserted-by":"crossref","first-page":"E2766","DOI":"10.1073\/pnas.1513023113","volume":"113","author":"S Frago","year":"2016","unstructured":"Frago S, Nicholls RD, Strickland M, Hughes J, Williams C, Garner L, Surakhy M, Maclean R, Rezgui D, Prince SN et al (2016) Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist. Proc Natl Acad Sci USA 113:E2766\u2013E2775","journal-title":"Proc Natl Acad Sci USA"},{"key":"314_CR16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/bj3090425","volume":"309","author":"R Froissart","year":"1995","unstructured":"Froissart R, Millat G, Mathieu M, Bozon D, Maire I (1995) Processing of iduronate 2-sulphatase in human fibroblasts. Biochem J 309:425\u2013430","journal-title":"Biochem J"},{"key":"314_CR17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s10545-007-0641-8","volume":"30","author":"AR Garcia","year":"2007","unstructured":"Garcia AR, Pan J, Lamsa JC, Muenzer J (2007) The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis 30:924\u2013934","journal-title":"J Inherit Metab Dis"},{"key":"314_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201708730","volume":"10","author":"HF Gleitz","year":"2018","unstructured":"Gleitz HF, Liao AY, Cook JR, Rowlston SF, Forte GM, D\u2019Souza Z, O\u2019Leary C, Holley RJ, Bigger BW (2018) Brain\u2010targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms. EMBO Mol Med 10:1\u201319","journal-title":"EMBO Mol Med"},{"key":"314_CR19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fgene.2023.1064924","volume":"14","author":"J Kido","year":"2023","unstructured":"Kido J, Sugawara K, Nakamura K (2023) Gene therapy for lysosomal storage diseases: current clinical trial prospects. Front Genet 14:32","journal-title":"Front Genet"},{"key":"314_CR20","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/21645515.2016.1268745","volume":"13","author":"SM Larson","year":"2017","unstructured":"Larson SM, Truscott LC, Chiou TT, Patel A, Kao R, Tu A, Tyagi T, Lu X, Elashoff D, De Oliveira SN (2017) Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy. Hum Vaccin Immunother 13:1094\u20131104","journal-title":"Hum Vaccin Immunother"},{"key":"314_CR24","unstructured":"LeBowitz JH, Maga J (2012) Lysosomal targeting peptides and uses thereof. United States Patent and Trademark Office, US20120213762A1"},{"key":"314_CR21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omtm.2022.09.010","volume":"27","author":"Q Liang","year":"2022","unstructured":"Liang Q, Catalano F, Vlaar EC, Pijnenburg JM, Stok M, van Helsdingen Y, Vulto AG, van der Ploeg AT, van Til NP, Pijnappel WWMPWMP (2022a) IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy. Mol Ther Methods Clin Dev 27:109\u2013130","journal-title":"Mol Ther Methods Clin Dev"},{"key":"314_CR22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtm.2022.04.016","volume":"25","author":"Q Liang","year":"2022","unstructured":"Liang Q, Vlaar EC, Catalano F, Pijnenburg JM, Stok M, van Helsdingen Y, Vulto AG, Unger WWJ, van der Ploeg AT, Pijnappel WWMPWMP et al (2022b) Lentiviral gene therapy prevents anti-human acid \u03b1-glucosidase antibody formation in murine Pompe disease. Mol Ther Methods Clin Dev 25:520\u2013532","journal-title":"Mol Ther Methods Clin Dev"},{"key":"314_CR23","doi-asserted-by":"crossref","first-page":"105037","DOI":"10.1016\/j.jprot.2023.105037","volume":"291","author":"Q Liang","year":"2024","unstructured":"Liang Q, Vlaar EC, Pijnenburg JM, Rijkers E, Demmers JAA, Vulto AG, van der Ploeg AT, van Til NP, Pijnappel WWMP (2024) Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease. J Proteom 291:105037","journal-title":"J Proteom"},{"key":"314_CR25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/biom11040611","volume":"11","author":"G Massaro","year":"2021","unstructured":"Massaro G, Geard AF, Liu W, Coombe\u2010tennant O, Waddington SN, Baruteau J, Gissen P, Rahim AA (2021) Gene therapy for lysosomal storage disorders: ongoing studies and clinical development. Biomolecules 11:611","journal-title":"Biomolecules"},{"key":"314_CR26","doi-asserted-by":"crossref","first-page":"e170199","DOI":"10.1172\/jci.insight.170199","volume":"8","author":"NK Meena","year":"2023","unstructured":"Meena NK, Randazzo D, Raben N, Puertollano R (2023) AAV-mediated delivery of secreted acid \u03b1-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice. JCI Insight 8:e170199","journal-title":"JCI Insight"},{"key":"314_CR27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/bj3260243","volume":"326","author":"G Millat","year":"1997","unstructured":"Millat G, Froissart R, Maire I, Bozon D (1997) Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue. Biochem J 326:243\u2013247","journal-title":"Biochem J"},{"key":"314_CR28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1159\/000527123","volume":"95","author":"BS Miller","year":"2022","unstructured":"Miller BS, Rogol AD, Rosenfeld RG (2022) The history of the insulin-like growth factor system. Horm Res Paediatr 95:619\u2013630","journal-title":"Horm Res Paediatr"},{"key":"314_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1326-5-16","volume":"5","author":"SS Minami","year":"2010","unstructured":"Minami SS, Cordova A, Cirrito JR, Tesoriero JA, Babus LW, Davis GC, Dakshanamurthy S, Turner RS, Pak DT, Rebeck GW et al (2010) ApoE mimetic peptide decreases A production in vitro and in vivo. Mol Neurodegener 5:16","journal-title":"Mol Neurodegener"},{"key":"314_CR30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ymgme.2020.06.007","volume":"130","author":"S Miwa","year":"2020","unstructured":"Miwa S, Watabe AM, Shimada Y, Higuchi T, Kobayashi H, Fukuda T, Kato F, Ida H, Ohashi T et al (2020) Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy. Mol Genet Metab 130:262\u2013273","journal-title":"Mol Genet Metab"},{"key":"314_CR31","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/endo.140.5.6732","volume":"140","author":"J Petrik","year":"1999","unstructured":"Petrik J, Pell JM, Arany E, McDonald TJ, Dean WL, Reik W, Hill DJ (1999) Overexpression of insulin-like growth factor-II in transgenic mice is associated with pancreatic islet cell hyperplasia. Endocrinology 140:2353\u20132363","journal-title":"Endocrinology"},{"key":"314_CR32","doi-asserted-by":"crossref","first-page":"2323.e1","DOI":"10.1016\/j.neurobiolaging.2010.05.025","volume":"32","author":"T Pflanzner","year":"2011","unstructured":"Pflanzner T, Janko MC, Andr\u00e9-Dohmen B, Reuss S, Weggen S, Roebroek AJM, Kuhlmann CRW, Pietrzik CU (2011) LRP1 mediates bidirectional transcytosis of amyloid-\u03b2 across the blood-brain barrier. Neurobiol Aging 32:2323.e1\u20132323.e11","journal-title":"Neurobiol Aging"},{"key":"314_CR33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2018.04.035","volume":"279","author":"H Ruan","year":"2018","unstructured":"Ruan H, Chai Z, Shen Q, Chen X, Su B, Xie C, Zhan C, Yao S, Wang H, Zhang M et al (2018) A novel peptide ligand RAP12 of LRP1 for glioma targeted drug delivery. J Controlled Release 279:306\u2013315","journal-title":"J Controlled Release"},{"key":"314_CR34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fmolb.2021.624988","volume":"8","author":"C Sevin","year":"2021","unstructured":"Sevin C, Deiva K (2021) Clinical trials for gene therapy in lysosomal diseases with CNS involvement. Front Mol Biosci 8:735","journal-title":"Front Mol Biosci"},{"key":"314_CR35","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1089\/hum.2022.141","volume":"33","author":"MC Smith","year":"2022","unstructured":"Smith MC, Belur LR, Karlen AD, Erlanson O, Podetz-Pedersen KM, McKenzie J, Detellis J, Gagnidze K, Parsons G, Robinson N et al (2022) Phenotypic correction of murine mucopolysaccharidosis type II by engraftment of ex vivo lentiviral vector-transduced hematopoietic stem and progenitor cells. Hum Gene Ther 33:1279\u20131292","journal-title":"Hum Gene Ther"},{"key":"314_CR36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2018.07.013","volume":"125","author":"N Tanaka","year":"2018","unstructured":"Tanaka N, Kida S, Kinoshita M, Morimoto H, Shibasaki T, Tachibana K, Yamamoto R (2018) Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS. Mol Genet Metab 125:53\u201358","journal-title":"Mol Genet Metab"},{"key":"314_CR37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpeds.2022.05.008","volume":"248","author":"AAM Vollebregt","year":"2022","unstructured":"Vollebregt AAM, Hoogeveen-Westerveld M, Ruijter GJ, van den Hout H, Oussoren E, van der Ploeg AT, Pijnappel WWMP (2022) Effect of anti-iduronate 2-sulfatase antibodies in patients with mucopolysaccharidosis type II treated with enzyme replacement therapy. J Pediatr 248:100\u2013107.e3","journal-title":"J Pediatr"},{"key":"314_CR38","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1012763026526","volume":"24","author":"YV Voznyi","year":"2001","unstructured":"Voznyi YV, Keulemans JLM, van Diggelen OP (2001) A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis 24:675\u2013680","journal-title":"J Inherit Metab Dis"},{"key":"314_CR39","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.str.2020.05.002","volume":"28","author":"Y Xu","year":"2020","unstructured":"Xu Y, Kirk NS, Venugopal H, Margetts MB, Croll TI, Sandow JJ, Webb AI, Delaine CA, Forbes BE, Lawrence MC (2020) How IGF-II binds to the human type 1 insulin-like growth factor receptor. Structure 28:786\u2013798.e6","journal-title":"Structure"},{"key":"314_CR40","doi-asserted-by":"crossref","unstructured":"Yoon JK, Schindler JW, Loperfido M, Baricordi C, DeAndrade MP, Jacobs ME, Treleaven C, Plasschaert RN, Yan A, Barese CN et al (2024) Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations. Mol Ther 32:3847\u20133864","DOI":"10.1016\/j.ymthe.2024.09.024"},{"key":"314_CR41","doi-asserted-by":"crossref","first-page":"1030453","DOI":"10.3389\/fendo.2023.1030453","volume":"14","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Qin S, Huai J, Yang H, Wei Y (2023) Overexpression of IGF2 affects mouse weight and glycolipid metabolism and IGF2 is positively related to macrosomia. Front Endocrinol 14:1030453","journal-title":"Front Endocrinol"},{"key":"314_CR42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ymthe.2004.02.017","volume":"9","author":"SP Zielske","year":"2004","unstructured":"Zielske SP, Lingas KT, Li Y, Gerson SL (2004) Limited lentiviral transgene expression with increasing copy number in an MGMT selection model: lack of copy number selection by drug treatment. Mol Ther 9:923\u2013931","journal-title":"Mol Ther"}],"updated-by":[{"DOI":"10.1038\/s44321-026-00492-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000}}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00314-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-025-00314-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00314-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:53:21Z","timestamp":1786978401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-025-00314-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,10]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1038\/s44321-025-00314-3","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ans T van der Ploeg (AvdP) has received consulting fees from Sanofi Genzyme and has provided consulting services, participated in advisory boards meetings and received grants for premarketing studies and research from industries via agreements between Erasmus MC and the industry. WWM Pim Pijnappel (WP) is cofounder and scientific advisor of LentiCure.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"16"}}